OXFORD: Biotech firm Oxford Biomedica, based at the Oxford Science Park, has reported encouraging new data from a trial of its anti-cancer drug Trovax.
The product, which has already been successfully tested on kidney and bowel cancer, has produced positive results in its first Phase II trial with 27 prostate cancer patients.
Dr Mike McDonald, Oxford BioMedica's chief medical officer, said: "With our partner, Sanofi-aventis,we believe that TroVax could play an important role in the treatment ofprostate cancer, addressing a significant unmet need for patients."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article